These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 16375690)
1. Augmenting T helper cell immunity in cancer. Knutson KL; Disis ML Curr Drug Targets Immune Endocr Metabol Disord; 2005 Dec; 5(4):365-71. PubMed ID: 16375690 [TBL] [Abstract][Full Text] [Related]
2. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Knutson KL; Disis ML Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587 [TBL] [Abstract][Full Text] [Related]
3. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291 [TBL] [Abstract][Full Text] [Related]
4. Identification of T helper epitopes from prostatic acid phosphatase. McNeel DG; Nguyen LD; Disis ML Cancer Res; 2001 Jul; 61(13):5161-7. PubMed ID: 11431355 [TBL] [Abstract][Full Text] [Related]
5. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. Lu J; Higashimoto Y; Appella E; Celis E J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075 [TBL] [Abstract][Full Text] [Related]
6. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide. Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040 [TBL] [Abstract][Full Text] [Related]
7. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer]. Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158 [TBL] [Abstract][Full Text] [Related]
8. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116 [TBL] [Abstract][Full Text] [Related]
9. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408 [TBL] [Abstract][Full Text] [Related]
10. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Giuntoli RL; Lu J; Kobayashi H; Kennedy R; Celis E Clin Cancer Res; 2002 Mar; 8(3):922-31. PubMed ID: 11895927 [TBL] [Abstract][Full Text] [Related]
11. Vaccines targeting helper T cells for cancer immunotherapy. Melssen M; Slingluff CL Curr Opin Immunol; 2017 Aug; 47():85-92. PubMed ID: 28755541 [TBL] [Abstract][Full Text] [Related]
12. Harnessing neoantigen specific CD4 T cells for cancer immunotherapy. Brightman SE; Naradikian MS; Miller AM; Schoenberger SP J Leukoc Biol; 2020 Apr; 107(4):625-633. PubMed ID: 32170883 [TBL] [Abstract][Full Text] [Related]
14. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells. Xiang J; Huang H; Liu Y J Immunol; 2005 Jun; 174(12):7497-505. PubMed ID: 15944248 [TBL] [Abstract][Full Text] [Related]
15. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. zum Büschenfelde CM; Metzger J; Hermann C; Nicklisch N; Peschel C; Bernhard H J Immunol; 2001 Aug; 167(3):1712-9. PubMed ID: 11466395 [TBL] [Abstract][Full Text] [Related]
16. Antigen organization regulates cluster formation and induction of cytotoxic T lymphocytes by helper T cell subsets. Stuhler G; Schlossman SF Proc Natl Acad Sci U S A; 1997 Jan; 94(2):622-7. PubMed ID: 9012834 [TBL] [Abstract][Full Text] [Related]
17. The wild-type sequence (wt) p53(25-35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53(264-272) peptide CD8+ T cells. Ito D; Albers A; Zhao YX; Visus C; Appella E; Whiteside TL; DeLeo AB J Immunol; 2006 Nov; 177(10):6795-803. PubMed ID: 17082593 [TBL] [Abstract][Full Text] [Related]
18. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes. Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194 [TBL] [Abstract][Full Text] [Related]
19. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. Davila E; Celis E J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094 [TBL] [Abstract][Full Text] [Related]
20. Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients. Tomita Y; Yuno A; Tsukamoto H; Senju S; Yoshimura S; Osawa R; Kuroda Y; Hirayama M; Irie A; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y Int J Cancer; 2014 Jan; 134(2):352-66. PubMed ID: 24734272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]